StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects - NCT05517902

Percentage of Participants Achieving Confirmed Complete Closure of StrataGraft Treatment Sites without Autograft within 12 Weeks of StrataGraft Application, Number of Participants With Treatment-emergent Adverse Events (TEAEs), Mean Percent Area of StrataGraft Treatment Site Closed at Week 12 Without Autograft Placement, Mean Percent Area of StrataGraft Treatment Site Autografted by Week 12